Close Menu

CHICAGO (GenomeWeb) – Two next-generation precision oncology drugs, one an EGFR inhibitor and an ALK inhibitor, have shown to be far more effective against advanced non-small cell lung cancer than older drugs in their class.

At the American Society of Clinical Oncology's annual meeting, researchers presented data from two head-to-head NSCLC trials, one comparing the first targeted EGFR inhibitor Iressa (gefitinib) against the next-generation dacomitinib; and another comparing the first ALK-inhibitor Xalkori (crizotinib) against newer agent Alecensa (alectinib).

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.